Alector, Inc. (NASDAQ:ALEC) Shares Sold by US Bancorp DE

US Bancorp DE decreased its holdings in shares of Alector, Inc. (NASDAQ:ALEC) by 40.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 13,762 shares of the company’s stock after selling 9,191 shares during the period. US Bancorp DE’s holdings in Alector were worth $64,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of Alector by 65.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,718 shares of the company’s stock worth $87,000 after purchasing an additional 7,395 shares during the last quarter. nVerses Capital LLC acquired a new stake in Alector in the 3rd quarter worth about $51,000. Creative Planning increased its position in shares of Alector by 54.2% during the third quarter. Creative Planning now owns 19,117 shares of the company’s stock worth $89,000 after purchasing an additional 6,723 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Alector by 73.1% in the second quarter. Cubist Systematic Strategies LLC now owns 92,218 shares of the company’s stock valued at $419,000 after buying an additional 38,947 shares during the last quarter. Finally, Algert Global LLC acquired a new position in shares of Alector during the 2nd quarter worth approximately $198,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Insiders Place Their Bets

In related news, insider Sara Kenkare-Mitra sold 13,926 shares of Alector stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $67,958.88. Following the completion of the transaction, the insider now directly owns 291,715 shares in the company, valued at approximately $1,423,569.20. This trade represents a 4.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Arnon Rosenthal sold 26,499 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $129,315.12. Following the sale, the chief executive officer now owns 1,948,746 shares in the company, valued at approximately $9,509,880.48. This trade represents a 1.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,722 shares of company stock worth $232,883 over the last three months. Company insiders own 9.10% of the company’s stock.

Analyst Ratings Changes

ALEC has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alector in a research note on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Alector in a research report on Thursday, November 7th.

Alector Stock Performance

Alector stock opened at $4.07 on Monday. The company has a market capitalization of $398.58 million, a PE ratio of -2.39 and a beta of 0.66. Alector, Inc. has a fifty-two week low of $3.66 and a fifty-two week high of $8.90. The firm has a 50 day moving average price of $5.10 and a 200 day moving average price of $5.12.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.10. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The business had revenue of $15.34 million during the quarter, compared to analysts’ expectations of $16.33 million. As a group, equities research analysts forecast that Alector, Inc. will post -1.87 earnings per share for the current year.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.